Banner - NPPA Connect

Opinion|Videos|December 20, 2024

Understanding Patient Comorbidities and Burden of Disease in Prurigo Nodularis

Author(s)Shawn Kwatra, MD, FAAD

A panelist discusses how prurigo nodularis is a chronic inflammatory skin condition that disproportionately affects middle-aged adults and those with immune disorders, causing intensely pruritic nodules that significantly impact quality of life through both physical discomfort and psychological distress.

Episodes in this series

1 KOL is featured in this series.

EP. 1 Understanding Patient Comorbidities and Burden of Disease in Prurigo Nodularis

1 KOL is featured in this series.

EP. 2 Advances in Systemic Treatment Options for Prurigo Nodularis

1 KOL is featured in this series.

EP. 3 Managing Moderate Prurigo Nodularis in a 52-Year-Old Female With Atopic Dermatitis

1 KOL is featured in this series.

EP. 4 Optimizing Severe Prurigo Nodularis Treatment in a 65-Year-Old Male With Multiple Comorbidities

1 KOL is featured in this series.

EP. 5 Practice Pearls for Managing Patients With Prurigo Nodularis

Please comment on the prevalence of prurigo nodularis and the patient subtypes who are primarily impacted by this condition.
- What are some of the comorbidities that are often associated with prurigo nodularis, and what are some of the challenges involved with the management of those comorbidities?
Based on your experience treating patients with this condition, what is the burden of disease for those with prurigo nodularis, particularly individuals with moderate-to-severe disease.
- How does this condition affect patients both physically and mentally?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Trending on Dermatology Times

Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension

Case Report Highlights Rural Care Gaps in Recurrent Merkel Cell Carcinoma

Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease

Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine

Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial